Is Roper Technologies (ROP) a risky stock?
As of July 21, 2026, Clavix grades Roper Technologies (ROP) B+ for risk, a composite score of 78 out of 100 on an A+ to F scale, which puts ROP in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ROP's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ROP scores on each, as of July 21, 2026.
What's moving ROP's risk right now
Company-specific signals Clavix flags behind ROP's current grade, drawn from recent news and filings as of July 21, 2026.
Guidance cuts or consensus estimate reductions signal near-term earnings pressure that typically precedes multiple contraction.
A significant institutional investor increased its conviction in ROP, signaling continued institutional confidence in the company and providing a modest tailwind for the stock's n…
The launch strengthens Roche's diagnostics franchise by addressing an unmet clinical need and positions the company to capture lab demand as new HDV therapies enter the market, su…
What a B+ grade means
On the Clavix A+ to F scale, ROP's composite of 78 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ROP or any security. Grades are risk indicators, not predictions of return. Data may be delayed.